⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9124679 | 0.90 | KDM4E (0.64) | — | |
| SCHEMBL4611607 | 0.88 | KDM4E (0.68) | — | |
| SCHEMBL5930050 | 0.84 | KDM4E (0.42) | — | |
| SCHEMBL31206390 | 0.74 | — | — | |
| SCHEMBL16130796 | 0.74 | — | — | |
| SCHEMBL31206703 | 0.74 | — | — | |
| SCHEMBL10857129 | 0.72 | — | — | |
| SCHEMBL8906547 | 0.71 | GAA (0.41) | — | |
| SCHEMBL19446195 | 0.70 | KDM4E (0.42) | — | |
| SCHEMBL5256777 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653946-A4 | GEOMETRICALLY RESTRICTED 3-CYCLOPENTYLIDENE-1,3-DIHYDROINDOL-2-ONES AS POTENT PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2007-04-04 | — | — | EP | claimed |
| CN-1942445-A | Novel quinoline-carbaxamides as JACK3 kinase modulators | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | CN | claimed |
| JP-2007501229-A | — | — | 2007-01-25 | — | — | JP | claimed |
| EP-1653946-A2 | GEOMETRICALLY RESTRICTED 3-CYCLOPENTYLIDENE-1,3-DIHYDROINDOL-2-ONES AS POTENT PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005016875-A2 | GEOMETRICALLY RESTRICTED 3-CYCLOPENTYLIDENE-1,3-DIHYDROINDOL-2-ONES AS POTENT PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-8735387-B2 | Oxazolopyrimidines as Edg-1 receptor agonists | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| CN-102159582-B | Oxazolopyrimidines as edg-1 receptor agonists | SANOFI AVENTIS | 2014-05-07 | — | — | CN | disclosed |
| EP-2583720-A1 | Oxazolopyrimidines as Edg-1 receptor agonists | SANOFI (FR) | 2013-04-24 | — | — | EP | disclosed |
| US-20110190490-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| EP-2318415-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010006704-A1 | OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | WO | disclosed |
| CN-1942445-A | Novel quinoline-carbaxamides as JACK3 kinase modulators | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | CN | disclosed |
| EP-1349852-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | Sugen, Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055517-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | CUI JINGRONG (US) | 2002-07-18 | — | — | WO | disclosed |